BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 14646387)

  • 1. Safety of subcutaneous specific immunotherapy with pollen allergen extracts for respiratory allergy.
    Arifhodzic N; Behbehani N; Duwaisan AR; Al-Mosawi M; Khan M
    Int Arch Allergy Immunol; 2003 Nov; 132(3):258-62. PubMed ID: 14646387
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety of inhalant allergen immunotherapy with mass units-standardized extracts.
    Nettis E; Giordano D; Pannofino A; Ferrannini A; Tursi A
    Clin Exp Allergy; 2002 Dec; 32(12):1745-9. PubMed ID: 12653166
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Systemic tolerability of specific subcutaneous immunotherapy with index-of-reactivity-standardized allergen extracts administered using clustered regimens: a retrospective, observational, multicenter study.
    Serrano P; Justicia JL; Sánchez C; Cimarra M; Fernández-Távora L; Orovitg A; Moreno C; Guerra F; Alvà V
    Ann Allergy Asthma Immunol; 2009 Mar; 102(3):247-52. PubMed ID: 19354072
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral allergy syndrome in patients with airborne pollen allergy treated with specific immunotherapy.
    Czarnecka-Operacz M; Jenerowicz D; Silny W
    Acta Dermatovenerol Croat; 2008; 16(1):19-24. PubMed ID: 18358104
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma.
    Roberts G; Hurley C; Turcanu V; Lack G
    J Allergy Clin Immunol; 2006 Feb; 117(2):263-8. PubMed ID: 16461125
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy with and without Seasonal Dose Adjustment.
    Albuhairi S; Sare T; Lakin P; El Khoury K; Crestani E; Schneider LC; Anzaldi R; Patterson A; Rachid R
    J Allergy Clin Immunol Pract; 2018; 6(5):1711-1716.e4. PubMed ID: 29339129
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study.
    Klimek L; Schendzielorz P; Pinol R; Pfaar O
    Clin Exp Allergy; 2012 Jun; 42(6):936-45. PubMed ID: 22909165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of specific immunotherapy with standardized allergenic extracts adsorbed on aluminium hydroxide.
    Wüthrich B; Gumowski PL; Fäh J; Hürlimann A; Deluze C; André C; Fadel R; Carat F
    J Investig Allergol Clin Immunol; 2001; 11(3):149-56. PubMed ID: 11831445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of omalizumab and specific immunotherapy is superior to immunotherapy in patients with seasonal allergic rhinoconjunctivitis and co-morbid seasonal allergic asthma.
    Kopp MV; Hamelmann E; Zielen S; Kamin W; Bergmann KC; Sieder C; Stenglein S; Seyfried S; Wahn U;
    Clin Exp Allergy; 2009 Feb; 39(2):271-9. PubMed ID: 19016798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Analysis of adverse reactions induced by subcutaneous immunotherapy against dust mite allergy in 234 cases with allergic rhinitis and asthma].
    Li MR; Wang XN; Jiang HD; Wang QY; Li YC; Lin J; Jin K; Zhang HL; Li CC
    Zhonghua Er Ke Za Zhi; 2012 Oct; 50(10):726-31. PubMed ID: 23302557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety of two cluster schedules for subcutaneous immunotherapy in allergic rhinitis or asthma patients sensitized to inhalant allergens.
    Pfaar O; Klimek L; Fischer I; Sieber J; Amoroso S; Moreno Aguilar C; Shah K; Mösges R
    Int Arch Allergy Immunol; 2009; 150(1):102-8. PubMed ID: 19339808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of risk factors for systemic adverse reactions to SCIT with natural depot allergen extracts: a retrospective study.
    Asero R
    Eur Ann Allergy Clin Immunol; 2015 Nov; 47(6):211-7. PubMed ID: 26549339
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated Up-Dosing of Subcutaneous Immunotherapy with a Registered Allergoid Birch Pollen Preparation.
    Buczyłko K; van der Werf JF; Boot D; van Ree R
    Int Arch Allergy Immunol; 2017; 172(3):183-186. PubMed ID: 28380494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phoenix sylvestris Roxb pollen allergy: a 2-year randomized controlled trial and follow-up study of immunotherapy in patients with seasonal allergy in an agricultural area of West Bengal, India.
    Chakraborty P; Roy I; Chatterjee S; Chanda S; Gupta-Bharracharya S
    J Investig Allergol Clin Immunol; 2006; 16(6):377-84. PubMed ID: 17153886
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Cluster-immunotherapy in seasonal allergic rhinitis: safety aspects of induction therapy with depot allergoids (Purethal)].
    Hansen I; Hörmann K; Stuck BA; Schneider-Gêne S; Mösges R; Klimek L
    Laryngorhinootologie; 2003 Aug; 82(8):558-63. PubMed ID: 12915987
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sublingual-oral administration of standardized allergenic extracts: phase 1 safety and dosing results.
    Esch RE; Bush RK; Peden D; Lockey RF
    Ann Allergy Asthma Immunol; 2008 May; 100(5):475-81. PubMed ID: 18517081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of recombinant and native timothy pollen (rPhl p 1, 2, 5, 6, 7, 11, 12 and nPhl p 4)- specific IgG4 antibodies induced by subcutaneous immunotherapy with timothy pollen extract in allergic patients.
    Rossi RE; Monasterolo G
    Int Arch Allergy Immunol; 2004 Sep; 135(1):44-53. PubMed ID: 15286445
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transient impact of omalizumab in pollen allergic patients undergoing specific immunotherapy.
    Kopp MV; Hamelmann E; Bendiks M; Zielen S; Kamin W; Bergmann KC; Klein C; Wahn U;
    Pediatr Allergy Immunol; 2013 Aug; 24(5):427-33. PubMed ID: 23799935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of allergen immunotherapy in the treatment of allergic rhinitis and asthma in real life.
    Zeldin Y; Weiler Z; Magen E; Tiosano L; Kidon MI
    Isr Med Assoc J; 2008 Dec; 10(12):869-72. PubMed ID: 19160945
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effect of 1-year specific immunotherapy with standardized house dust mite vaccine on mild to moderate allergic asthmatic patients].
    Wang HY; Lin XP; Hao CL; Zhang CQ; Sun BQ; Zheng JP; Chen P; Sheng JY; Wu A; Zhong NS
    Zhonghua Jie He He Hu Xi Za Zhi; 2006 Oct; 29(10):679-87. PubMed ID: 17129496
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.